Study Reports Overall Comparable Cancer Risk for Women Undergoing Fertility Treatments, Identifies Specific Variations

Fertility Treatments and Cancer Risk: An Australian Study Offers Reassurance

A recent large-scale Australian study has found that women who have undergone fertility treatments, including in vitro fertilization (IVF), have an overall cancer rate comparable to that of the general female population. While the study identified slight increases in the risk of certain cancers, such as uterine, ovarian, and melanoma, it also noted lower risks for others, including cervical and respiratory tract cancers.

Researchers emphasize that the absolute number of additional cases for the increased risks was small, and the study's observational nature means it cannot establish a direct causal link between fertility treatments and cancer.

Study Overview and Methodology

The study investigated a potential link between fertility treatments and cancer development, a long-standing area of concern regarding hormonal medications and ovarian procedures. Researchers utilized individual health records from Medicare and the Pharmaceutical Benefits Scheme to identify 417,984 women who received fertility treatments in Australia between 1991 and 2018. This extensive data was then linked to the Australian Cancer Database to track cancer diagnoses.

Participants, with a median age of 32–34 years, were followed for an average of approximately one decade. The cohort included:

• 274,676 women who underwent treatments involving egg removal, such as IVF (categorized as Assisted Reproductive Technologies or ART).
• 120,739 women who had specialist treatments without egg removal, primarily intrauterine insemination with ovarian stimulation (IUI/OS).
• 175,510 women who received prescriptions for clomiphene citrate, a medication used to induce ovulation (categorized as Ovulation Induction).

Some women received multiple types of treatment. Cancer rates in these women were statistically compared to age- and location-matched women in the general population.

Overall Cancer Incidence

The study reported that the all-cancer incidence in women exposed to ART or IUI with ovarian stimulation was similar to that of the general population. A slight overall increase (4%) in cancer risk was observed following clomiphene citrate treatment.

Specific Cancer Incidence Observations

While the overall risk remained comparable, detailed analysis by cancer type revealed specific differences.

• Uterine Cancer: Risk was higher across all treatment groups: 23% with ART, 32% with IUI/OS, and 83% with clomiphene citrate. Most excess cases were Type 1 (endometrioid) uterine cancers.
• Ovarian Cancer: Incidence was higher in ART (23%) and IUI/OS (18%) groups, primarily in endometrioid and serous subtypes. The highest risk was noted within the first year post-treatment and among women with six or more treatment cycles.
• Melanoma: Both in situ and invasive melanoma were found to be 7% to 15% more common across all cohorts.
• Breast Cancer: In situ breast cancer rates were 24% higher in ART patients, with increases appearing around six years after the first treatment. Invasive breast cancer rates were initially lower but were observed to be higher among women over 50 or those followed for six or more years after ART or IUI-OS.
• Thyroid Cancer: A 19% higher risk was found in the clomiphene citrate group, specifically in women who had given birth and within 3-5 years of treatment.

In absolute terms, these increases were very small, ranging from less than one to fewer than seven additional cases per 100,000 person-years for specific cancer types. For the clomiphene citrate cohort, this corresponded to approximately nine additional cancer cases per 100,000 women per year across all cancers combined.

Conversely, the study found lower risks for certain cancers in the treated groups:

• Cervical Cancer: Risk was decreased by 39% to 48% across all treatment groups.
• Respiratory Tract Cancers: Risk was 30% to 38% lower across all treatment groups.
• Other Cancers: Lower risks were also noted for acute myeloid leukemia, pancreatic cancer (25% lower in ART/IUI-OS groups), and cancers of the kidney, bladder, and unknown primary site (28% to 45% lower in the ART cohort).

Context and Contributing Factors

Researchers noted that factors beyond fertility treatment itself could contribute to the observed cancer risk variations.

• Potential reasons for increased risks include:

  • Pre-existing conditions associated with infertility, such as endometriosis (a risk factor for ovarian cancer) and polycystic ovarian syndrome.
  • Other factors like reproductive history, use of hormonal contraceptives, and specific genetic susceptibilities.
  • Fair skin tone, more prevalent in Caucasian women who commonly receive fertility treatments, is a risk factor for melanoma.

• Potential reasons for decreased risks include:

  • Lower smoking rates among women receiving fertility treatment.
  • Increased medical surveillance and cervical cancer screening due to clinician encouragement before and during treatment.
  • Higher socioeconomic status in some patient populations.

Implications and Limitations

The study's overall findings were described by researchers as reassuring regarding the total incidence of cancer for individuals who have undergone or are considering fertility treatments.

While some cancers were found to be more common, the absolute number of these additional cases was small, similar to risks associated with other medical interventions.

The study's observational design does not allow for a definitive conclusion on whether fertility treatments directly cause or prevent cancer. Other factors, such as the differing health and socio-demographic profiles of women undergoing fertility treatments, may influence cancer risk. The study did not include data on the specific reasons for infertility or pregnancy attempts, nor did it track participants beyond approximately ten years, meaning long-term risks may evolve with age.

Recommendations

Women and their healthcare providers are encouraged to make informed decisions regarding fertility treatments, considering the potential changes in cancer risk. Continued participation in routine cancer screening programs is advised for all eligible women, including those considering or having received fertility treatment. Concerns about cancer risk should be discussed with a doctor. Researchers emphasized the need for continued investigation into cancer risks associated with fertility treatment to inform personalized risk management strategies and long-term monitoring guidelines.